Human Characterised Hepatocytes are isolated from whole human livers that are
not suitable for liver transplantation.
plateable and suspension hepatocytes are evaluated for post-thaw yield and
viability, morphology, and plating efficiency. Characterized cryoplateable
human hepatocytes are also evaluated for CYP450 basal and mRNA induction levels
following treatment with known inducers of CYP1A2 (Omeprazole 50μM), CYP2B6
(Phenobarbital 1mM), and CYP3A4 (Rifampicin 10μM). Each lot is guaranteed to
contain a minimum of 3 million cells per vial, have a viability of > 85%,
and maintain > 75% confluency for a minimum period of 5 days.
cryosuspension human hepatocytes are evaluated for the following enzymatic
activity panel: CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2D6, CYP2E1, CYP3A4
(Midazolam), CYP3A4 (Testosterone), GEN, SULT, UGT, and AO. Each lot is
guaranteed to contain a minimum of 3 million cells per vial and have a
viability of > 75%.
lots can also be analysed for purity through FACS analysis for the cell
markers: CD147, CD166, and CD45. All of the lot-specific information will be
reported on the Certificate of Analysis (CoA).
see our protocol/lot dependent for detailed instructions. Primary Human Hepatocytes
protocols do change slightly depending on the lot. Some lots need to have an
additional Percoll step. Culture vessels must be coated with Type I Collagen:
ax3799 is recommend.
ax3754-1 Primary Hepatocyte Thaw Medium and ax3752-1 Primary Hepatocyte
Maintenance Medium for cryosuspension (non plateable) lots. Use
ax3751-1 Primary Hepatocyte Plating Medium for Plateable lots.
cells are tested and confirmed negative for HIV-1, HIV-2, HBV and HCV as
detected by PCR. The cells are confirmed to be negative for mycoplasma and
other detectable microbial contamination.